$486.00
0.50%
Nasdaq, Nov 28, 07:46 pm CET
ISIN
US91307C1027
Symbol
UTHR

United Therapeutics Corporation Stock price

$486.00
+70.66 17.01% 1M
+170.36 53.97% 6M
+133.16 37.74% YTD
+107.87 28.53% 1Y
+215.31 79.54% 3Y
+353.36 266.41% 5Y
+333.37 218.42% 10Y
+450.30 1,261.34% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-2.43 0.50%

New AI Insights on United Therapeutics Corporation Insights AI Insights on United Therapeutics Corporation

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$20.9b
Enterprise Value
$18.2b
Net debt
positive
Cash
$2.8b
Shares outstanding
42.9m
Valuation (TTM | estimate)
P/E
18.1 | 17.3
P/S
6.7 | 6.4
EV/Sales
5.8 | 5.6
EV/FCF
16.3
P/B
3.2
Financial Health
Equity Ratio
87.5%
Return on Equity
18.6%
ROCE
22.4%
ROIC
28.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.1b | $3.3b
EBITDA
$1.6b | $1.7b
EBIT
$1.5b | $1.6b
Net Income
$1.3b | $1.2b
Free Cash Flow
$1.1b
Growth (TTM | estimate)
Revenue
13.5% | 13.7%
EBITDA
13.4% | 11.1%
EBIT
12.9% | 9.5%
Net Income
14.5% | 0.8%
Free Cash Flow
24.3%
Margin (TTM | estimate)
Gross
88.6%
EBITDA
51.3% | 51.7%
EBIT
48.7%
Net
40.7% | 36.8%
Free Cash Flow
35.7%
More
EPS
$26.9
FCF per Share
$26.0
Short interest
5.1%
Employees
1k
Rev per Employee
$2.2m
Show more

Is United Therapeutics Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

United Therapeutics Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a United Therapeutics Corporation forecast:

16x Buy
73%
6x Hold
27%

Analyst Opinions

22 Analysts have issued a United Therapeutics Corporation forecast:

Buy
73%
Hold
27%

Financial data from United Therapeutics Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
3,128 3,128
14% 14%
100%
- Direct Costs 357 357
17% 17%
11%
2,772 2,772
13% 13%
89%
- Selling and Administrative Expenses 705 705
17% 17%
23%
- Research and Development Expense 544 544
9% 9%
17%
1,605 1,605
13% 13%
51%
- Depreciation and Amortization 83 83
24% 24%
3%
EBIT (Operating Income) EBIT 1,522 1,522
13% 13%
49%
Net Profit 1,272 1,272
14% 14%
41%

In millions USD.

Don't miss a Thing! We will send you all news about United Therapeutics Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

United Therapeutics Corporation Stock News

Neutral
Investors Business Daily
9 days ago
The Big Cap 20 pick to watch is United Therapeutics stock, which is up 72% in the last few months.
Neutral
Seeking Alpha
12 days ago
United Therapeutics Corporation ( UTHR ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Harrison Silvers - Manager of Investor Relations James Edgemond - CFO & Treasurer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division Welcome, everyone, to Jefferies London Healthca...
Neutral
Seeking Alpha
20 days ago
United Therapeutics Corporation ( UTHR ) UBS Global Healthcare Conference 2025 November 10, 2025 9:30 AM EST Company Participants Patrick Poisson - Executive VP of Technical Operations Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Terence Flynn - Morgan Stanley, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, ev...
More United Therapeutics Corporation News

Company Profile

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Head office United States
CEO Martine Rothblatt
Employees 1,305
Founded 1996
Website www.unither.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today